Mar 3 2008, 11:42 AM EST
MARKETWIRE
OncoMune LLC announced positive results demonstrating that the genetic inhibition of BORIS expression leads to programmed cell death of cancer cells. The results will be presented at the upcoming American Association of Cancer Researchers (AACR) Annual Meeting in San Diego, April 12-16 by Dr. Christopher Dougherty, Research Assistant Professor of Biomedical Science at Florida Atlantic University in collaboration with OncoMune.
"OncoMune and collaborators have previously published that the vaccination to the Brother of the Regulator of Imprinted Sites (BORIS) induces immunity to a variety of cancers, including glioma, leukemia, and breast cancer. The current data provides validation at the molecular level that BORIS is not only a marker of cancer cells, but is functionally critical for tumor cell survival," Dr. Dougherty said.
The experiments performed used a process called "RNA interference (RNAi)" to specifically "silence" the expression of BORIS in cancer cells. The results demonstrated that the cancer cells in which the BORIS gene was blocked induced their own death, whereas non-cancer cells treated with the agent that blocks BORIS were unaffected.
"OncoMune has filed several patent applications covering molecular entities capable of inducing RNA interference against BORIS. The scientific acceptance of our work supports the possibility of OncoMune expanding its therapeutic pipeline to include siRNA therapeutics," said Boris Reznik, Chairman of OncoMune.
About OncoMune
OncoMune is an oncology-focused biotechnology company working on targeting the epigenetic cancer causing transcription factor BORIS. BORIS is expressed in all cancer tumors tested to date and not expressed in non-malignant tissue. The company's therapeutics pipeline consists of immunology, small molecule, and genetic-based approaches to destroying cancer cells expressing BORIS.
Contact: Lindsey Hall (786) 388-0700 Email Contact www.oncomune.com
SOURCE: OncoMune
ADVERTISEMENT
INTERVIEW:
(BIO) BANKING IN LUXEMBOURG - Interview with Robert Hewitt, Ph.D., CEO, Integrated Biobank of Luxembourg, and European Editor, Biopreservation and Biobanking (published by Mary Ann Liebert, Inc.)
...MORE
NewsArticles Blogs| Most Viewed | Most Emailed | Top Searches |
|---|---|---|
| Unclog the Innovation Bottleneck at our Nation’s Universities | ||
| (Bio) Banking in Luxembourg | ||
ADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All